All respiratory syncytial virus articles
-
NewsHuman ‘mini-noses’ help understand why RSV infections are more severe in children than in adults
Why does RSV affect babies more severely? To better understand the cellular reasons behind this age-related difference, researchers compared infant and adult human nose organoids, also called mini-noses, regarding their susceptibility and response to infection.
-
NewsProtecting infants against respiratory syncytial virus this winter — ECDC issues advice
ECDC has issued rapid scientific advice for policymakers and public health authorities on ways to mitigate the impact of RSV disease among infants through immunisation and to support intensified efforts to protect them from RSV across Europe.
-
NewsNot just a common cold: studies show RSV’s severity and impact on long-term health
Often confused for a common cold, respiratory syncytial virus (RSV) can in fact be serious and should be studied more closely. Researchers found that the illness could be of comparable severity to other more well-known respiratory viral infections (RVIs) – such as influenza and COVID-19.
-
NewsAI can speed antibody design to thwart novel viruses: study
Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study
-
NewsRSV vaccines safe and effective, Cochrane review finds
A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including older adults and infants.
-
NewsEven healthy children can be severely affected by RSV
It is not only premature babies and children with underlying diseases who suffer from serious respiratory syncytial virus (RSV) infections. Even healthy, full-term babies are at significant risk of intensive care or prolonged hospitalisation – especially during the first three months of life.
-
NewsOne shot of RSV vaccine effective against hospitalization in older adults for two seasons
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons, according to a new study.
-
NewsNew jab protects babies from serious lung infection, study shows
Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.
-
NewsMonoclonal antibody nirsevimab provides strong protection against severe RSV in infants
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis.
-
NewsExperts recommend mAb protection against RSV as standard care for all infants
While RSV poses a serious threat to the health of infants and young children, prophylactic mAbs offer safe and effective protection for an entire season, according to international health organizations.
-
NewsWhy some kids get sicker: The hidden power of nose bacteria
A scoping review unravels how bacterial colonization in the respiratory tract impacts both the severity of respiratory syncytial virus (RSV) infections and long-term respiratory health in children.
-
NewsPapers outline 4 advances for inactivating infectious viruses and bacteria
Four papers provide insights into novel antiviral compounds and methods to inactivate infectious viral particles and bacteria.
-
NewsRSV vaccines effective, but more people need to get them
Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.
-
NewsResearchers confront new US and global challenges in vaccinations of adults
Decreasing vaccination rates now threaten the huge beneficial impacts of vaccinations in the U.S. and globally. Researchers discuss the barriers including increasing vaccine hesitancy and new clinical and public health challenges in vaccinations of U.S. adults.
-
NewsNew images of RSV may expose stubborn virus’s weak points
Using cryo-electron tomography, researchers have revealed details of molecules and structures essential to RSV’s form and function.
-
NewsScientists pinpoint new drug target for RSV
Scientists have discovered how the dangerous Respiratory Syncytial Virus (RSV) defuses our immune response and, in doing so, they have pinpointed an exciting new target for drug developers.
-
NewsStudy backs RSV vaccine safety during pregnancy
Vaccinating mothers against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes, according to a new study.
-
NewsBiotech companies leverage novel tools to develop drugs for RSV
Reporter structures that can be introduced into cells for use in drug screening assays emit fluorescent or bioluminescent light at different intensities when RSV genes are inhibited by the potential antiviral agents being tested.
-
NewsNew tool may help prioritize high-risk infants for RSV immunization
On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious infections.
-
NewsSevere lung damage caused when flu is followed by infection with measles-like virus
Infection with a measles-like virus causes catastrophic lung failure in ferrets previously infected with influenza virus or respiratory syncytial virus, according to a new study.